5.59%
-1.12%
-18.87%
-17.34%
-33.04%
-33.12%
-21.04%
AI Spotlight on BOI
Company Description
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.The company offers non-proprietary, proprietary, branded homeopathic medicines.Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders.
The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders.In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds.Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests.
The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail.Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Market Data
| Last Price | 26.45 |
| Change Percentage | 5.59% |
| Open | 26.45 |
| Previous Close | 25.05 |
| Market Cap ( Millions) | 459 |
| Volume | 694 |
| Year High | 37.5 |
| Year Low | 24.8 |
| M A 50 | 26.57 |
| M A 200 | 31.16 |
Financial Ratios
| FCF Yield | 7.18% |
| Dividend Yield | 5.10% |
| ROE | 6.18% |
| Debt / Equity | 3.98% |
| Net Debt / EBIDTA | -67.54% |
| Price To Book | 1.23 |
| Price Earnings Ratio | 19.38 |
| Price To FCF | 13.92 |
| Price To sales | 0.95 |
| EV / EBITDA | 7.39 |
News
- Sep -06 - Air Liquide And 2 Other Reliable Dividend Stocks On Euronext Paris
- Aug -22 - Top 3 Dividend Stocks To Watch On Euronext Paris
- Aug -07 - Top Dividend Stocks On Euronext Paris For August 2024
- Jul -18 - Top Three Dividend Stocks On Euronext Paris For July 2024
- Jul -03 - Boiron And Two More High-Yielding Dividend Stocks From Euronext Paris
- Jun -18 - Boiron And 2 Other Euronext Paris Dividend Stocks To Consider
- Jun -03 - Unveiling 3 Euronext Paris Dividend Stocks With Yields Up To 8.3%
- May -17 - Boiron And Two More Premier Dividend Stocks On Euronext Paris
- Jul -07 - Polygon Labs Promotes Boiron to CEO; President Wyatt to Depart
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Homeopathic Specialties
Expected Growth : 2.5 %
What the company do ?
Homeopathic Specialties from Boiron SA offer a range of natural remedies for various health conditions, providing gentle and effective solutions for everyday health concerns.
Why we expect these perspectives ?
Boiron SA's Homeopathic Specialties segment growth of 2.5% is driven by increasing consumer preference for natural and organic products, rising awareness about health and wellness, and expanding distribution channels. Additionally, growing demand from emerging markets and strategic partnerships contribute to the segment's growth.
Segment n°2 -> Common Name Homeopathic Medicines
Expected Growth : 2.8 %
What the company do ?
Common Name Homeopathic Medicines from Boiron SA refers to natural remedies made from highly diluted substances, gentle and safe for the whole family, manufactured by Boiron SA.
Why we expect these perspectives ?
Boiron SA's 2.8% growth in Homeopathic Medicines is driven by increasing consumer preference for natural and organic products, rising awareness about health and wellness, and expanding distribution channels. Additionally, the company's strong brand recognition, product innovation, and strategic partnerships contribute to its growth momentum.
Segment n°3 -> Other Health Products
Expected Growth : 3.2 %
What the company do ?
Boiron SA's Other Health Products segment includes homeopathic medicines and supplements for various health conditions, such as allergies, stress, and sleep disorders.
Why we expect these perspectives ?
Boiron SA's Other Health Products segment growth of 3.2% is driven by increasing consumer adoption of natural and homeopathic remedies, expansion into new markets, and strategic partnerships. Additionally, growing demand for self-care and wellness products, as well as rising healthcare costs, contribute to the segment's growth.
Boiron Sa Products
| Product Range | What is it ? |
|---|---|
| Oscillococcinum | A homeopathic medicine used to relieve flu-like symptoms such as body aches, fever, and chills. |
| Arnicare | A line of topical creams, gels, and ointments used to relieve pain and reduce inflammation. |
| Chestal | A homeopathic cough syrup used to relieve coughs and congestion. |
| ColdCalm | A homeopathic medicine used to relieve cold and flu symptoms such as sneezing, runny nose, and congestion. |
| Stodal | A homeopathic cough syrup used to relieve coughs and congestion. |
Boiron SA's Porter Forces
Threat Of Substitutes
Boiron SA faces moderate threat from substitutes, as there are alternative homeopathic products available in the market, but the company's strong brand reputation and wide distribution network help to mitigate this threat.
Bargaining Power Of Customers
Boiron SA's customers have low bargaining power due to the company's strong brand reputation and wide distribution network, which limits the ability of customers to negotiate prices or demand customized products.
Bargaining Power Of Suppliers
Boiron SA's suppliers have moderate bargaining power due to the company's dependence on high-quality raw materials, but the company's long-term relationships with suppliers help to mitigate this threat.
Threat Of New Entrants
Boiron SA faces low threat from new entrants due to the company's strong brand reputation, wide distribution network, and high barriers to entry in the homeopathic products market.
Intensity Of Rivalry
Boiron SA operates in a highly competitive homeopathic products market, with several established players competing for market share, which increases the intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 3.36% |
| Debt Cost | 6.23% |
| Equity Weight | 96.64% |
| Equity Cost | 6.23% |
| WACC | 6.23% |
| Leverage | 3.48% |
Boiron SA : Quality Control
Boiron SA passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PSG.DE | PharmaSGP Holding SE manufactures over-the-counter drugs, and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage cream … |
| VETO.PA | Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas … |
| SECARE.ST | Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells pet healthcare products. It offers ProDen PlaqueOff powder, a food supplement for cats and dogs, which reduce the … |
| FAGR.BR | Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it … |
| RJF.MC | Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products and food supplements. The company offers prescription medicines, OTCs, medical devices, and cosmetics. Its products include … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Reig Jofre
A-Score
1-Year Total Return ->
🥈
Fagron
A-Score
1-Year Total Return ->
🥉
PharmaSGP Holding
A-Score
1-Year Total Return ->
4
Boiron
A-Score
1-Year Total Return ->
5
Vetoquinol
A-Score
1-Year Total Return ->
6
